{"id":"W1543680891","doi":"10.1016/j.ejheart.2007.12.006","title":"Efficacy and Tolerability of Adding an Angiotensin Receptor Blocker in Patients with Heart Failure Already Receiving an Angiotensin-Converting Inhibitor Plus Aldosterone Antagonist, With or Without a Beta Blocker. Findings from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM)-Added Trial","year":2008,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University; Hamilton Medical Research Group; McMaster Children's Hospital; McMaster University Medical Centre","funders":"","keywords":"Spironolactone; Medicine; Candesartan; Beta blocker; Discontinuation; Heart failure; Angiotensin receptor; Tolerability; Internal medicine; Aldosterone; Hyperkalemia; ACE inhibitor; Placebo; Calcium channel blocker; Angiotensin II; Angiotensin-converting enzyme; Adverse effect; Blood pressure","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003183845,0.0009232408,0.002141337,0.0002766112,0.0003104722,0.001043961,0.0006573757,0.001359982,0.002562875],"category_scores_gemma":[0.00393446,0.0004341874,0.0030801,0.0003072271,0.0006378684,0.0007974132,0.0004170241,0.002566797,0.0003606057],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005787988,"about_ca_system_score_gemma":0.0006008602,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007194675,"about_ca_topic_score_gemma":0.001906328,"domain_scores_codex":[0.9985864,0.0008254333,0.0001384527,0.0001789442,0.0001515595,0.0001192005],"domain_scores_gemma":[0.9975687,0.000994075,0.0005916085,0.0001569818,0.0001035046,0.0005851213],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9661284,0.002779845,0.00989754,0.0007602565,0.004012914,0.00006939939,0.00004143197,0.0003455571,0.001235267,0.00004388639,0.0005352561,0.01415028],"study_design_scores_gemma":[0.7765793,0.1581636,0.05379727,0.0001996661,0.007875788,0.0001651443,0.00006476914,0.001165477,0.0008513828,0.000206246,0.0008855268,0.00004578873],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9863815,0.01014405,0.0001897682,0.0004884716,0.0003632321,0.0002799838,0.0006728076,0.00002639596,0.001453679],"genre_scores_gemma":[0.995379,0.001986616,0.0002749593,0.0005538826,0.0005087747,0.0001885089,0.0006529659,0.000005240205,0.0004500736],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003183845,"threshold_uncertainty_score":0.01683795,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03276913259568871,"score_gpt":0.2856124967044748,"score_spread":0.2528433641087861,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}